Peptide-specific T cell response to Mycobacterium tuberculosis:: Clinical spectrum, compartmentalization, and effect of chemotherapy

被引:61
作者
Wilkinson, RJ
Vordermeier, HM
Wilkinson, KA
Sjölund, A
Moreno, C
Pasvol, G
Ivanyi, J
机构
[1] Hammersmith Hosp, MRC, TB & Related Infect Unit, Imperial Coll,Sch Med, London W12 0HS, England
[2] Northwick Pk Hosp & Clin Res Ctr, Imperial Coll, Sch Med, Wellcome Ctr Clin Trop Med, Harrow HA1 3UJ, Middx, England
[3] Univ Stockholm, Arrhenius Lab, Dept Immunol, S-10691 Stockholm, Sweden
基金
英国惠康基金;
关键词
D O I
10.1086/515336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The T cell repertoire of 59 patients with untreated tuberculosis was compared with that of 46 bacille Calmette-Guerin-vaccinated controls by assaying the proliferative responses to six permissively recognized peptides from the 16-, 19-, and 38-kDa molecules of Mycobacterium tuberculosis. A trend from higher to lower reactivity following this order: vaccinated controls > lymph node disease > localized extrapulmonary > pulmonary > pleural was seen for 4 of the peptides (P <.03), The decreased response of blood lymphocytes from patients with pleural tuberculosis was partially accounted for by sequestration of peptide-responsive cells within the pleural fluid, Chemotherapy "reversed" the depressed proliferative responses of patients with pulmonary and pleural tuberculosis depending on the peptide origin, being greatest for peptides of 16 kDa, transient for those of 19 kDa, and least for those of 38 kDa, These data demonstrate antigen specificity in the decreased responsiveness of patients with tuberculosis.
引用
收藏
页码:760 / 768
页数:9
相关论文
共 57 条
[1]   STRUCTURE AND MAPPING OF ANTIGENIC DOMAINS OF PROTEIN ANTIGEN-B, A 38,000-MOLECULAR-WEIGHT PROTEIN OF MYCOBACTERIUM-TUBERCULOSIS [J].
ANDERSEN, AB ;
HANSEN, EB .
INFECTION AND IMMUNITY, 1989, 57 (08) :2481-2488
[3]   Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4(+) T cells via CD40 ligand [J].
Balashov, KE ;
Smith, DR ;
Khoury, SJ ;
Hafler, DA ;
Weiner, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :599-603
[4]  
BARNES PF, 1989, J IMMUNOL, V142, P1114
[5]   CYTOKINE PRODUCTION AT THE SITE OF DISEASE IN HUMAN TUBERCULOSIS [J].
BARNES, PF ;
LU, SZ ;
ABRAMS, JS ;
WANG, E ;
YAMAMURA, M ;
MODLIN, RL .
INFECTION AND IMMUNITY, 1993, 61 (08) :3482-3489
[6]  
Bloom Barry R., 1994, P531
[7]   HUMAN T-CELL RESPONSES TO SECRETED ANTIGEN FRACTIONS OF MYCOBACTERIUM-TUBERCULOSIS [J].
BOESEN, H ;
JENSEN, BN ;
WILCKE, T ;
ANDERSEN, P .
INFECTION AND IMMUNITY, 1995, 63 (04) :1491-1497
[8]   CLINICAL-VALUE OF THE MEASUREMENT OF MYCOBACTERIUM-TUBERCULOSIS SPECIFIC ANTIBODY IN PULMONARY TUBERCULOSIS [J].
BOTHAMLEY, GH ;
RUDD, R ;
FESTENSTEIN, F ;
IVANYI, J .
THORAX, 1992, 47 (04) :270-275
[9]   ELEVATED INTERLEUKIN-2 RECEPTOR LEVEL IN PATIENTS WITH ACTIVE PULMONARY TUBERCULOSIS AND THE CHANGES FOLLOWING ANTITUBERCULOSIS CHEMOTHERAPY [J].
CHAN, CHS ;
LAI, CKW ;
LEUNG, JCK ;
HO, ASS .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (01) :70-73
[10]  
Chan S. L., 1994, P141